Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03235245
Title	Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)
Acronym	EBIN
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	European Organisation for Research and Treatment of Cancer - EORTC
Indications	skin melanoma mucosal melanoma
Therapies	Binimetinib + Encorafenib Ipilimumab + Nivolumab
Age Groups:	senior \| adult
Covered Countries	POL \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU